The Wait Before the Medicine: Inside Prior Authorization's Grip on American Prescriptions

A Decision Made Twice

American patients encounter an unusual structural feature in their care: a prescription can be clinically correct, clinically necessary, and clinically urgent, and still not be filled. Between the prescriber's signature and the pharmacy's dispensing label sits a third decision-maker — the payer's utilization management apparatus — which reviews a share of prescriptions for medical necessity before agreeing to pay.

Prior authorization is the most visible form of that review. Step therapy is its close relative. Together they represent a deliberate policy choice: that certain categories of spending warrant a check before the money moves. The rationale is not irrational. Specialty drugs, advanced imaging, and high-cost biologics can cost more in a month than many patients spend on healthcare in a year, and unmanaged use of these products drives premiums for everyone.

The objection is not to review in principle. It is to the widening gap between what the review was designed to do and how it functions in everyday practice — where a clinician's judgment is second-guessed by a criteria set the clinician cannot see, and where the delay itself becomes a clinical event.

Step Therapy and the Fail-First Logic

Step therapy requires patients to try one or more lower-cost therapies before a payer will cover a preferred, typically more expensive option. The logic is straightforward: many patients respond well to first-line treatment, so require the cheaper trial first.

The logic breaks down in two places. First, it assumes the trial is clinically appropriate — that the patient has no contraindication, no history of failure on that exact agent, and no reason to expect intolerance. Second, it assumes the trial is quick. A fail-first sequence for a chronic condition can consume months, each step requiring its own fill, its own monitoring, and its own period of assessment before the next is authorized.

For conditions where time-to-treatment affects outcomes — inflammatory disease, oncology, severe mental illness — the administrative interval is not neutral. It is disease progression with paperwork attached.

What the 2026 Landscape Looks Like

The Centers for Medicare & Medicaid Services finalized a rule in early 2024 that imposes meaningful operational requirements on certain payers, including Medicare Advantage organizations, Medicaid and CHIP managed care plans, and qualified health plans on the federal exchanges. The provisions phased in across 2026 and 2027, and they are worth understanding in plain terms.

• Shorter turnaround clocks. Standard prior authorization decisions are subject to defined response windows, with faster timelines for expedited requests. A request that misses the window has consequences for the payer.
• Specific denial reasons. A denial must state the reason and, where applicable, identify the criteria used.
• Electronic exchange. Payer-to-payer and provider-facing data exchange requirements are intended to reduce the fax-and-telephone workflow that has defined utilization management for a generation.
• Public reporting. Payers must publish certain metrics on authorization volume and denial rates, which gives employers, researchers, and regulators something firmer than anecdote.

What the rule does not do is eliminate prior authorization, cap its use, or reach the self-funded employer plans that cover a large share of working-age Americans under ERISA. State legislatures have moved in that direction — dozens have enacted reforms over the past several years covering response times, gold-carding programs, and step-therapy exceptions — but state law generally governs fully insured plans, not self-funded ones. The result is a patchwork in which a patient's experience depends substantially on which type of plan their employer purchased.

Building a Record That Survives Review

Appeals are won or lost on documentation, and the documentation burden falls disproportionately on prescribing clinicians. Patients can still improve their own odds by making sure the right information reaches the right file.

• Establish the clinical rationale in writing. A chart note explaining why the requested agent is preferred over the formulary alternative is more useful than a diagnosis code alone.
• Document prior failures precisely. Drug name, dose, duration, and reason for discontinuation. 'Intolerant' is weaker than 'discontinued after six weeks due to elevated transaminases.'
• Include objective findings. Lab values, imaging results, functional scores, and specialist consultation notes carry more weight than symptom descriptions.
• Request the criteria. Ask the payer to state the specific coverage criteria applied to your drug. Denials that cite nothing are easier to challenge.
• Note the urgency. If the delay threatens function, hospitalization, or disease progression, say so explicitly and request expedited review.

The Appeal Ladder

Most policies offer at least three levels of recourse. The first is an internal appeal, reviewed by the payer's own clinicians. The second is an external review conducted by an independent organization, available in most states for denials involving medical judgment and required in many federally regulated plans. The third is expedited review, which compresses the timeline when a standard review would jeopardize the patient's health.

Patients should know that these processes have deadlines, that they are typically initiated by the prescriber's office rather than the patient, and that the most common failure mode is not a denial but a lapse — an appeal that is never filed because no one was assigned to file it. Asking a clinician's office directly who is handling the appeal, and when, is a reasonable and effective question.

Why This Endures

The uncomfortable answer is that prior authorization works as designed for the party that designed it. It reduces spending on categories of care where variation is high and prices are steep. That it also imposes costs — administrative labor on clinicians, delays on patients, and occasional harm — is a known trade-off rather than an unforeseen defect.

The policy conversation in 2026 has shifted from whether to have utilization management to how tightly to bound it: response-time enforcement, gold-carding programs that exempt high-performing clinicians, continuity-of-care protections for patients mid-treatment, and transparency requirements that make denial patterns legible. Those are modest instruments, but they address the central complaint accurately. The problem is rarely that a payer asked a question. It is that the answer took three weeks, and no one was accountable for the waiting.